<DOC>
	<DOCNO>NCT00940316</DOCNO>
	<brief_summary>RATIONALE : Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , panitumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Panitumumab may also stop growth colorectal cancer block blood flow tumor . Drugs use chemotherapy , irinotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether erlotinib hydrochloride give together panitumumab effective without irinotecan treating patient metastatic colorectal cancer . PURPOSE : This randomized phase II trial study give erlotinib hydrochloride together panitumumab see well work without irinotecan hydrochloride second-line therapy treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib Panitumumab With Without Chemotherapy Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient metastatic colorectal cancer treat erlotinib hydrochloride panitumumab versus without irinotecan hydrochloride second-line therapy . Secondary - Determine time disease progression time treatment failure patient treat regimen . - Determine safety regimens patient . - Determine effect regimens downstream target EGFR skin rash associate pharmacologic EGFR inhibition ( exploratory ) . - Determine association KRAS mutation response EGFR inhibition ( exploratory ) . OUTLINE : This multicenter study . Patients stratify accord wild-type Kras tumor ( 6/6 UGT1A1 v 6/7 UGT1A1 ) , randomize 1 2 treatment arm . Patients wild-type Kras tumor 7/7 UGT1A1 receive treatment arm III . - Arm I : Patients receive oral erlotinib hydrochloride daily day 1-14 , panitumumab IV 30-90 minute day 1 , irinotecan hydrochloride IV 90 minute day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . - Arm II : Patients receive oral erlotinib hydrochloride daily day 1-14 panitumumab IV 30-90 minute day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Upon disease progression , patient receive irinotecan hydrochloride arm I . - Arm III : Patients receive erlotinib hydrochloride panitumumab arm II . Skin biopsy blood sample may collect analysis . After completion study therapy , patient follow every 6 week .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Metastatic disease Biopsy either primary cancer metastatic site require Tumor express wildtype Kras mutation Progressive disease within 3 month treatment firstline fluorouracil ( 5FU ) oxaliplatinbased chemotherapy OR evidence metastatic disease within 6 month complete adjuvant therapy 5FU oxaliplatin Measurable disease define ≥ 1 lesion accurately measure ≥ 1 dimension ( long diameter record ) ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 6 month ANC &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 9 g/dL Creatinine &lt; 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN ( &lt; 2 mg/dL ) AST and/or ALT &lt; 3 time ULN ( &lt; 5 time ULN liver metastasis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent malignancy require therapy except minor surgery nonmelanoma skin cancer removal No interstitial lung disease symptom ( e.g. , dyspnea cough ) include follow significant condition : Parenchymal lung disease Metastatic disease Pulmonary infection PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior EGFR inhibitor , irinotecan hydrochloride , secondline chemotherapy regimens More 4 week since prior radiotherapy No concurrent investigational agent No concurrent anticancer treatment modality ( e.g. , radiotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>